Stay updated on Nivolumab for ALK+ ALCL: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.
Latest updates to the Nivolumab for ALK+ ALCL: Clinical Trial page
- Check3 days agoChange DetectedThe Locations section was updated with new entries for Paris and Villejuif in Val-de-Marne, and some existing address lines were removed or reformatted.SummaryDifference0.9%
- Check10 days agoChange DetectedOnly minor layout and wording tweaks observed; core study information remains unchanged.SummaryDifference0.1%
- Check17 days agoChange DetectedPage revision updated: v3.4.3 replaced with v3.5.0.SummaryDifference0.1%
- Check25 days agoNo Change Detected
- Check53 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 removed, a minor UI/version update that does not affect study details or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check60 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; no study content or critical details were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check67 days agoChange DetectedA glossary toggle was added and QC-related labels were capitalized or reworded, including "Last Update Submitted that Met QC Criteria" and "No FEAR Act Data", along with a new "Revision: v3.4.0" tag. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
Stay in the know with updates to Nivolumab for ALK+ ALCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.